Magnisense issued U.S. patent for magnetic immunoassays
Magnisense has received the patent from U.S. Patent and Trademark Office titled "Method for Analyzing a Mixture of Biological and/or Chemical Components using Magnetic Particles and Device for the Implementation of said Method" -- a patent which had already been granted in Europe in 2009.
Magnisense's assays are based on the use of magnetic beads as markers. The priority patent covers the MIAtek technology used by the company to develop its next-generation magnetic immunoassays for human and animal diagnostics, food safety and environmental protection.
The Paris-based Magnisense said the patent is an essential piece of the company’s intellectual property and constitutes the cornerstone of a portfolio of five patent families. The patent will expire in 2021 in Europe and in 2025 in the U.S. The expiry dates for the remaining four families run as far as 2028.
Magnisense's assays are based on the use of magnetic beads as markers. The priority patent covers the MIAtek technology used by the company to develop its next-generation magnetic immunoassays for human and animal diagnostics, food safety and environmental protection.
The Paris-based Magnisense said the patent is an essential piece of the company’s intellectual property and constitutes the cornerstone of a portfolio of five patent families. The patent will expire in 2021 in Europe and in 2025 in the U.S. The expiry dates for the remaining four families run as far as 2028.